The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes

Slides:

Advertisements

Similar presentations

Refractive Surgical Question Rudy M.M.A. Nuijts, MD, PhD Journal of Cataract & Refractive Surgery Volume 40, Issue 3, Pages (March 2014) DOI: /j.jcrs

Advertisements

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Lutein + Zeaxanthin and Omega-3 Fatty Acids for Age-Related.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Supplementing Milk Replacer with Omega-3 Fatty Acids from Fish Oil on Immunocompetence and Health of Jersey Calves M.A. Ballou, E.J. DePeters Journal of.

Eicosapentaenoic Acid Eicosapentaenoic acid Eicosapentaenoic acid (EPA) is an omega-3 fatty acid.

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements

Effects of 2 Different Doses of Pregabalin on Morphine Consumption and Pain After Abdominal Hysterectomy: A Randomized, Double-Blind Clinical Trial Aytaç.

Lipid abnormalities in foreign-born and US-born patients in a medical group Jawali Jaranilla, MD, MPH, Terese DeFor, MS, Gabriela Vazquez Benitez, PhD,

Individual omega-9 monounsaturated fatty acids and mortality—The Ludwigshafen Risk and Cardiovascular Health Study Graciela E. Delgado, MSc, Bernhard.

Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: An updated meta-analysis and review of research gaps Kevin C. Maki, PhD,

Patient and Physician Perspectives on Administration of the PCSK9 Monoclonal Antibody Alirocumab, an Injectable Medication to Lower LDL-C Levels† Eli.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

Fatty acids, inflammation, and asthma

Erythrocyte long-chain omega-3 fatty acid levels are inversely associated with mortality and with incident cardiovascular disease: The Framingham Heart.

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

An assessment by the Statin Cognitive Safety Task Force: 2014 update

An assessment by the Statin Muscle Safety Task Force: 2014 update

An assessment by the Statin Liver Safety Task Force: 2014 update

Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled.

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients Evan Stein, MD, Harold Bays, MD, Michael Koren,

Emerging LDL therapies: Mipomersen—antisense oligonucleotide therapy in the management of hypercholesterolemia Peter P. Toth, MD, PhD, FAAFP, FICA, FNLA,

Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial Erik S.G. Stroes, MD, PhD, Andrey.

Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.

Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C- III levels in patients from the MARINE and ANCHOR studies Christie.

Predictors of first-year statin medication discontinuation: A cohort study Heli Halava, MD, Risto Huupponen, MD, PhD, Jaana Pentti, BSc, Mika Kivimäki,

Fatty acid oxidation in normotriglyceridemic men

Effect of fatty and lean fish intake on lipoprotein subclasses in subjects with coronary heart disease: A controlled trial Arja T. Erkkilä, PhD, Ursula.

The UK Paediatric Familial Hypercholesterolaemia Register: Statin-related safety and 1- year growth data Steve E. Humphries, PhD, FRCP, Jackie Cooper,

A Randomized, Double-Blind, Placebo-Controlled Trial of Nutritional Supplementation During Acute Illness Salah Gariballa, MD, Sarah Forster, MSc, Stephen.

Effects of icosapent ethyl on lipoprotein particle concentration and size in statin-treated patients with persistent high triglycerides (the ANCHOR Study)

A 3-year study of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia Gisle Langslet, MD, Andrei Breazna, PhD, Euridiki.

Fatty acids, inflammation, and asthma

Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial John J.P.

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Effects of Xuezhikang in patients with dyslipidemia: A multicenter, randomized, placebo- controlled study Patrick M. Moriarty, MD, Eli M. Roth, MD, Adam.

J. W. Balder, MD, PhD, P. J. Lansberg, MD, PhD, M. H. Hof, MSc, A

Emma J. Aarnio, MSc (Pharm), Janne A

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Paul D. Thompson, MD, John Rubino, MD, Matthew J. Janik, MD, Diane E

Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1 Omar Abdel-Razek, MD, Singh N.

Comparative effects of an acute dose of fish oil on omega-3 fatty acid levels in red blood cells versus plasma: Implications for clinical utility William.

An assessment by the Statin Intolerance Panel: 2014 update

Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a)

Extended-Release Niacin/Laropiprant Lowers Serum Phosphorus Concentrations in Patients with Type 2 Diabetes and Mild Hyperphosphatemia Andrew G. Bostom,

Corn oil improves the plasma lipoprotein lipid profile compared with extra-virgin olive oil consumption in men and women with elevated cholesterol: Results.

Go on-pump or off-pump in diabetic patients?

Effects of free omega-3 carboxylic acids and fenofibrate on liver fat content in patients with hypertriglyceridemia and non-alcoholic fatty liver disease:

Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia G. Kees Hovingh, MD,

Effect of Omega-3 Fatty Acids on Plasma Level of 8-Isoprostane in Kidney Transplant Patients Mohammad Ramezani, PharmD, PhD, Fatemeh Nazemian, MD, Jamal.

Practice Notes from the AAAAI

The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study Michael Davidson, MD, Michael Stevenson, RPh, PhD, Andrew Hsieh,

Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial

Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia Raul D. Santos, Frederick J. Raal,

Sokunthea Peou, PharmD, Brittany Milliard-Hasting, MD, Sachin A

Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT.

Christopher S. Penet, Brian H. Annex, MD, Kelly T. Gregory, R

Diabetes is associated with an increased risk of cardiovascular disease in patients with familial hypercholesterolemia Martine Paquette, MSc, Sophie.

Efficacy and safety of lipoprotein apheresis in children with homozygous familial hypercholesterolemia: A systematic review Ilse K. Luirink, MD, Jim.

Higher long-term adherence to statins in rural patients at high atherosclerotic risk Matthew R. Peverelle, MD, BBiomed, Arul Baradi, MBChB, Sarang Paleri,

Can Low-Radiation Coronary Computed Tomography Angiography Improve Upon Clinical Risk Assessment in Patients with Familial Hypercholesterolemia?* Anna.

A Clinical Pharmacist Patient-Safety Initiative to Reduce Against-Label Prescribing of Statins with Cyclosporine Donald G. Lamprecht, PharmD, Anne M.

Practice Notes from the AAAI

Prediction of Cardiovascular Disease Events by Lipoprotein(a) According to LDL-C in Older High Risk Adults Nathan D. Wong, PhD, Shravanthi R. Gandra,

Emerging low-density lipoprotein (LDL) therapies: Management of severely elevated LDL cholesterol—The role of LDL-apheresis Mary P. McGowan, MD, FNLA

Ming-Der Chen, PhD, Yuh-Min Song, MD Mayo Clinic Proceedings

Long-term clinical results of microsomal triglyceride transfer protein inhibitor use in a patient with homozygous familial hypercholesterolemia Anna.

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary Terry A. Jacobson, MD, Matthew.

Presentation transcript:

The effects of vitamin D and omega-3 fatty acid co-supplementation on glycemic control and lipid concentrations in patients with gestational diabetes Mehri Jamilian, MD, Mansooreh Samimi, MD, Faraneh Afshar Ebrahimi, MD, Teibeh Hashemi, MD, Mohsen Taghizadeh, PhD, Maryamalsadat Razavi, MD, Marzieh Sanami, BSc, Zatollah Asemi, PhD Journal of Clinical Lipidology Volume 11, Issue 2, Pages 459-468 (March 2017) DOI: 10.1016/j.jacl.2017.01.011 Copyright © 2017 National Lipid Association Terms and Conditions

Figure 1 Summary of patient flow diagram. 1Individuals received 50,000 IU vitamin D every 2 weeks plus placebo for omega-3 fatty acids twice a day; 2individuals received 1000 mg omega-3 fatty acids (360 mg eicosapentaenoic acid and 240 mg docosahexaenoic acid) twice a day plus placebo for vitamin D every 2 weeks; 3individuals received 50,000 IU vitamin D every 2 weeks plus 1000 mg omega-3 fatty acids twice a day. Journal of Clinical Lipidology 2017 11, 459-468DOI: (10.1016/j.jacl.2017.01.011) Copyright © 2017 National Lipid Association Terms and Conditions